TrialThe oncologist2026

Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3.

Apostolia Maria Tsimberidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.